(21683) Phase 2b open-label clinical study to evaluate the tolerability and safety of an initiation dose of 5 mg of Vericiguat in participants with chronic heart failure with reduced ejection fraction

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507682-25-00

Acronym

21683 "VELOCITY"

Enrollment

111

Registered

2024-05-08

Start date

2024-05-13

Completion date

2024-07-29

Last updated

2024-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure with reduced ejection fraction

Brief summary

Treatment tolerability, defined as the completion of the two-week 5 mg dose without discontinuation of study intervention, Treatment tolerability, defined as the completion of the two-week 5 mg dose without moderate to severe symptomatic hypotension between Visit 1 and Visit 2

Detailed description

Any AE reported between Visit 1 and 2, Absence of AE related to study intervention between Visit 1 and Visit 2., Continuous intake of study intervention between Visit 1 and Visit 2 or restart of study intervention after any temporary interruption.

Interventions

DRUGBAY 1021189

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Treatment tolerability, defined as the completion of the two-week 5 mg dose without discontinuation of study intervention, Treatment tolerability, defined as the completion of the two-week 5 mg dose without moderate to severe symptomatic hypotension between Visit 1 and Visit 2	—

Secondary

Measure	Time frame
Any AE reported between Visit 1 and 2, Absence of AE related to study intervention between Visit 1 and Visit 2., Continuous intake of study intervention between Visit 1 and Visit 2 or restart of study intervention after any temporary interruption.	—

Countries

Hungary, Italy, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026